ES2146314T3 - Vacuna contra infecciones micobacterianas. - Google Patents

Vacuna contra infecciones micobacterianas.

Info

Publication number
ES2146314T3
ES2146314T3 ES95919492T ES95919492T ES2146314T3 ES 2146314 T3 ES2146314 T3 ES 2146314T3 ES 95919492 T ES95919492 T ES 95919492T ES 95919492 T ES95919492 T ES 95919492T ES 2146314 T3 ES2146314 T3 ES 2146314T3
Authority
ES
Spain
Prior art keywords
micobacterial
vaccine against
infections
leprosy
tuberculosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95919492T
Other languages
English (en)
Inventor
Douglas Bruce Lowrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Application granted granted Critical
Publication of ES2146314T3 publication Critical patent/ES2146314T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/464817—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UNA ESTRUCTURA DE UN ACIDO NUCLEICO DESNUDO QUE CONTIENE UNA SECUENCIA DE CODIFICACION QUE CODIFICA UNA PROTEINA DE ESTRES MICOBACTERIANA O ANTIGENO RICO EN PROLINA O UN FRAGMENTO ANTIGENICAMENTE EFECTIVO DEL MISMO ENLAZADO DE FORMA OPERATIVA A UN PROMOTOR CAPAZ DE EXPRESAR LA SECUENCIA DE CODIFICACION ANTEDICHA EN UNA CELULA HUESPED DE UN MAMIFERO QUE ES UTIL COMO VACUNA CONTRA UNA INFECCION MICOBACTERIANA TAL COMO LA TUBERCULOSIS Y LA LEPRA.
ES95919492T 1994-05-18 1995-05-18 Vacuna contra infecciones micobacterianas. Expired - Lifetime ES2146314T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9409985A GB9409985D0 (en) 1994-05-18 1994-05-18 Vaccine against mycobacterial infections

Publications (1)

Publication Number Publication Date
ES2146314T3 true ES2146314T3 (es) 2000-08-01

Family

ID=10755365

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95919492T Expired - Lifetime ES2146314T3 (es) 1994-05-18 1995-05-18 Vacuna contra infecciones micobacterianas.

Country Status (11)

Country Link
US (2) US6492145B1 (es)
EP (1) EP0804230B1 (es)
JP (2) JP4435870B2 (es)
KR (1) KR970703165A (es)
AT (1) ATE189961T1 (es)
AU (1) AU702162B2 (es)
CA (1) CA2190515C (es)
DE (1) DE69515340T2 (es)
ES (1) ES2146314T3 (es)
GB (1) GB9409985D0 (es)
WO (1) WO1995031216A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
GB9706078D0 (en) * 1997-03-24 1997-05-14 Chiron Spa Screening method and proteins and dna identified thereby
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
KR100992646B1 (ko) 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
US20070098735A1 (en) * 2005-10-29 2007-05-03 Chandawarkar Rajiv Y Methods for the Elimination of Pathogens and Other Particulate Agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68924162T2 (de) 1988-06-15 1996-04-25 Medical Res Council Stressproteine und verwendungen dafür.
ATE165516T1 (de) 1989-03-21 1998-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
JP5163646B2 (ja) * 2007-07-19 2013-03-13 パナソニック株式会社 画像表示装置

Also Published As

Publication number Publication date
KR970703165A (ko) 1997-07-03
US6492145B1 (en) 2002-12-10
CA2190515A1 (en) 1995-11-23
AU2529095A (en) 1995-12-05
EP0804230A1 (en) 1997-11-05
DE69515340D1 (de) 2000-04-06
US20020198168A1 (en) 2002-12-26
JP4435870B2 (ja) 2010-03-24
WO1995031216A1 (en) 1995-11-23
GB9409985D0 (en) 1994-07-06
AU702162B2 (en) 1999-02-18
CA2190515C (en) 2007-11-13
ATE189961T1 (de) 2000-03-15
JP2007332149A (ja) 2007-12-27
DE69515340T2 (de) 2000-10-19
JPH10500128A (ja) 1998-01-06
EP0804230B1 (en) 2000-03-01

Similar Documents

Publication Publication Date Title
ES2146314T3 (es) Vacuna contra infecciones micobacterianas.
TR200002179T2 (tr) Kristalin teriparatid.
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
PL338001A1 (en) Integrin-bonding peptides and their application
DE69715861D1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
KR880700670A (ko) 알파-msh의 동족체의 국소적용으로 메라노싸이트를 자극시키는 방법 및 이에 사용될 수 있는 조성물
HRP20020787B1 (en) Method of treatment using ligand-immunogen conjugates
ATE73460T1 (de) Peptide aus alpha-aminoboronsaeuren.
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
ES2035064T3 (es) Aposito para heridas.
IT1184878B (it) Metodo di trattamento della fibra di poliarilammide
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
IT8168340A0 (it) Composizione per la tintura di fibre cheratiniche in particolare capelli umani e procedimento per il suo impiego
IT8720479A0 (it) Espressione migliorata di interleuchina-2 umana in cellule di mammiferi.
FR2550205B1 (fr) Proteines humaines, antisera et necessaires experimentaux
DE69534186D1 (de) Impfstoff gegen Streptokokkeninfektionen der Gruppe A
PT781095E (pt) Celulas contendo receptores chamariz cd4 e moleculas e metodos com elas relacionados
ATE245443T1 (de) Verfahren zur herstellung von konzentrierten lösungen von fibronectin ohne puffer
DE69121598D1 (de) Verfahren, um das Verpacken von sterilisiertem Mineralwasser vorzubereiten sowie verpacktes, sterilisiertes Mineralwasser
DE3872591D1 (de) Tampon aus elastischem schwammaterial, insbesondere scheidentampon.
ATE203768T1 (de) Diagnose und behandlung von streptococus oder enterococus infektionen
BR9907485A (pt) Chumaço, método para sua produção e bandagem adesiva usando o dito chumaço
AR223346A1 (es) Un conjunto sujetador de rieles de clavar de ferrocarril,una abrazadera y un asiento de aplicacion en dicho conjunto
ES2014042A6 (es) Un procedimiento para la preparacion de una composicion de 1-(2'-desoxi -2' fluor -b- d- arabinofuranosil) -5-etiluracilo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 804230

Country of ref document: ES